Texas ibogaine trials face funding gap as federal support looms

Texas' plan to fund ibogaine trials with a $50 million budget hit a roadblock when no private company matched the funds, as required by state law. The federal government, however, has stepped in to potentially fill this gap, according to The Center Square.

Federal intervention in Texas ibogaine trials

The Texas Health and Human Services Commission announced that no drug company submitted a proposal meeting the state's matching fund requirements. As a result, Texas intends to proceed with its own research program, although the cost remains unspecified. Meanwhile, an executive order signed by former President Donald Trump on April 18 directed the U.S. Department of Health and Human Services (HHS) to allocate at least $50 million to partner with states on psychedelic research.

Regulatory and funding hurdles

The federal initiative, known as EVIDENT, is managed by the Advanced Research Projects Agency for Health (ARPA-H) and aims to fund up to $139.4 million for behavioral health research. At least $50 million of this is earmarked to match state investments in psychedelic research, including ibogaine. However, Texas Senate Bill 2308 prohibits the state from disbursing its funds until matching funds are secured from non-state sources.

Implications of federal funding

Katharine Harris, a drug policy fellow at Rice University, noted that replacing private funds with federal money shifts the financial risk to taxpayers. This move could diverge from the legislative intent of fostering a public-private partnership. Despite this, the state's claim to a portion of revenue from intellectual property generated by the trials remains intact unless legislative changes occur.

Why it matters

The potential federal funding is significant as it could enable Texas to advance ibogaine research despite the lack of private investment. Ibogaine, a Schedule I controlled substance, is being studied for its potential to treat substance use disorders and other mental health issues. However, it carries known risks, including cardiac effects and potential brain injury, making rigorous clinical trials essential.

The FDA recently published a request for information on trial designs for early-phase ibogaine studies, with a focus on safety and efficacy. This initiative, part of the ASCENT-IBO program, underscores the ongoing interest and need for structured research into ibogaine's therapeutic potential.

The outcome of these funding and regulatory developments could shape the future of psychedelic research in Texas and beyond, highlighting the complex interplay between state and federal roles in advancing medical research.